Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer

Autor: Kazumi Sano, Kazuhiko Hanada, Kazuhiko Nakadate
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Male
Cancer Research
Scab formation
Lung Neoplasms
Side effect
Drug-Related Side Effects and Adverse Reactions
Afatinib
EGFR
Minocycline
Pharmacology
NSCLC
Skin Diseases
lcsh:RC254-282
03 medical and health sciences
Mice
0302 clinical medicine
Carcinoma
Non-Small-Cell Lung
Genetics
medicine
Animals
Humans
Epidermal growth factor receptor
Lung cancer
Protein Kinase Inhibitors
Skin repair
Transepidermal water loss
biology
integumentary system
business.industry
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Anti-Bacterial Agents
ErbB Receptors
Disease Models
Animal
030104 developmental biology
Improvement skin disorder
Oncology
030220 oncology & carcinogenesis
biology.protein
Quality of Life
business
Minocycline application
medicine.drug
Research Article
Zdroj: BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Cancer
ISSN: 1471-2407
DOI: 10.1186/s12885-020-06797-2
Popis: Background While epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) exert a breakthrough effect, the incidence of skin disorders as a side effect has significantly reduced patients’ quality of life. This study aimed to develop a treatment for inflammatory ulcers as one of the side effects of afatinib (Giotrif®), a second-generation EGFR-TKI, and established a skin disorder mouse model to investigate the protective effect of minocycline. Methods First, under inhalation anesthesia with isoflurane, the back of a male ddy mouse was shaved, and afatinib petrolatum was applied alone or in combination with minocycline to observe the state of the skin and measure transepidermal water transpiration (TEWL). Next, afatinib was administered orally to mice, and minocycline petrolatum was applied to observe whether the skin disorder was prevented and its effect on repair of the skin disorder. Results Skin injury occurred on the back of the mouse following afatinib (1 mg/g in petrolatum) application, and scab formation was observed. Application of minocycline prevented and improved the skin disorder caused by afatinib. When the minocycline-petrolatum mixture was applied to the mouse that developed the skin disorder, a significant improvement in TEWL was observed, and skin repair was observed macroscopically. Conclusions These results suggest that minocycline petrolatum applied locally prevents and repairs afatinib-induced skin disorders of non-small cell lung cancer patients. Histological examination of skin has provided insights into the mechanism of the occurrence of afatinib-related skin disorder and suggested the efficacy of minocycline topical application in clinical practice.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje